A challenge to all. A primer on inter-country differences of high-need, high-cost patients.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 21 12 2018
accepted: 06 05 2019
entrez: 20 6 2019
pubmed: 20 6 2019
medline: 26 2 2020
Statut: epublish

Résumé

Across countries, a small group of patients accounts for the majority of health care spending. These patients are more likely than other patients to experience problems with quality and safety in their care, suggesting that efforts targeting efficiency and quality among this population might have significant payoffs for health systems. Better understanding of similarities and differences in patient characteristics and health care use in different countries may ultimately inform further efforts to improve care for HNHC patients in these health systems. We conducted a cross-sectional descriptive study using one year of patient-level data on high-cost patients in seven high-income OECD member countries. Countries were selected based on availability of detailed information (large enough samples of claims, administrative, and survey data of high-cost patients). We studied concentration of spending among high-cost patients, characteristics of high-cost patients, and per capita spending on high-cost patients. Cost-concentration of the top 5% of patients varied across countries, from 41% in Japan to 60% in Canada, driven primarily by variation in the top 1% of spenders. In general, high-cost patients were more likely to be female (57.7% on average), had a significant number of multi-morbidities (up to on average 10 major diagnostic categories (ICD chapters), and had a lower socioeconomic status. Characteristics of high-cost patients varied as well: median age ranged from 62 in the Netherlands to 75 in Germany and the difference in socioeconomic status is particularly stark in the US. Lastly, utilization, particularly for inpatient care, varied with an average number of inpatient days ranging from 6.6 nights (US) to 97.7 nights in Japan. In this descriptive study, there is substantial variation in the cost concentration, characteristics, and per capita spending on high-cost patient populations across high-income countries. Differences in the way that health systems are structured likely explains some of this variation, which suggests the potential of cross-system learning opportunities. Our findings highlight the need for further studies including comparable performance metrics and institutional analysis.

Sections du résumé

BACKGROUND
Across countries, a small group of patients accounts for the majority of health care spending. These patients are more likely than other patients to experience problems with quality and safety in their care, suggesting that efforts targeting efficiency and quality among this population might have significant payoffs for health systems. Better understanding of similarities and differences in patient characteristics and health care use in different countries may ultimately inform further efforts to improve care for HNHC patients in these health systems.
METHODS
We conducted a cross-sectional descriptive study using one year of patient-level data on high-cost patients in seven high-income OECD member countries. Countries were selected based on availability of detailed information (large enough samples of claims, administrative, and survey data of high-cost patients). We studied concentration of spending among high-cost patients, characteristics of high-cost patients, and per capita spending on high-cost patients.
FINDINGS
Cost-concentration of the top 5% of patients varied across countries, from 41% in Japan to 60% in Canada, driven primarily by variation in the top 1% of spenders. In general, high-cost patients were more likely to be female (57.7% on average), had a significant number of multi-morbidities (up to on average 10 major diagnostic categories (ICD chapters), and had a lower socioeconomic status. Characteristics of high-cost patients varied as well: median age ranged from 62 in the Netherlands to 75 in Germany and the difference in socioeconomic status is particularly stark in the US. Lastly, utilization, particularly for inpatient care, varied with an average number of inpatient days ranging from 6.6 nights (US) to 97.7 nights in Japan.
INTERPRETATION
In this descriptive study, there is substantial variation in the cost concentration, characteristics, and per capita spending on high-cost patient populations across high-income countries. Differences in the way that health systems are structured likely explains some of this variation, which suggests the potential of cross-system learning opportunities. Our findings highlight the need for further studies including comparable performance metrics and institutional analysis.

Identifiants

pubmed: 31216286
doi: 10.1371/journal.pone.0217353
pii: PONE-D-18-36504
pmc: PMC6583982
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0217353

Déclaration de conflit d'intérêts

The authors have read the journal's policy and the authors of this manuscript have the following competing interests: LL and AP are paid employees of OptiMedis AG. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

JAMA. 2016 Oct 25;316(16):1657-1658
pubmed: 27669168
N Engl J Med. 2016 Sep 8;375(10):909-11
pubmed: 27602661
JAMA. 2017 Nov 7;318(17):1668-1678
pubmed: 29114831
Health Aff (Millwood). 2001 Nov-Dec;20(6):233-41
pubmed: 11816664
Health Aff (Millwood). 2007 May-Jun;26(3):808-16
pubmed: 17485760
JAMA Intern Med. 2013 Nov 11;173(20):1879-85
pubmed: 24043127
Health Aff (Millwood). 2016 Jan;35(1):28-35
pubmed: 26733698
Health Aff (Millwood). 2015 Sep;34(9):1531-7
pubmed: 26355055
BMJ Open. 2017 Nov 12;7(11):e017775
pubmed: 29133323
JAMA. 2017 Aug 8;318(6):515-516
pubmed: 28750110
Inquiry. 2009-2010 Winter;46(4):405-17
pubmed: 20184167
Med Care. 1990 Feb;28(2):112-23
pubmed: 2105413
Health Aff (Millwood). 2017 Apr 1;36(4):640-648
pubmed: 28373329
Health Aff (Millwood). 2011 Dec;30(12):2437-48
pubmed: 22072063
CMAJ. 2016 Feb 16;188(3):182-188
pubmed: 26755672
N Engl J Med. 2016 Dec 8;375(23):2218-2220
pubmed: 27959672
Med J Aust. 2006 Apr 17;184(8):393-7
pubmed: 16618238
Eur J Health Econ. 2005 Dec;Suppl:2-10
pubmed: 16270212
JAMA. 2018 Mar 13;319(10):1024-1039
pubmed: 29536101

Auteurs

Marit A C Tanke (MAC)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Radboudumc, Nijmegen, the Netherlands.
Commonwealth Fund Harkness Fellowship, New York, New York, United States of America.

Yevgeniy Feyman (Y)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Boston University School of Public Health, Boston, Massachusetts, United States of America.

Enrique Bernal-Delgado (E)

Institute for Health Sciences in Aragon, Zaragoza, Aragon, Spain.

Sarah R Deeny (SR)

The Health Foundation, London, United Kingdom.

Yuichi Imanaka (Y)

Kyoto University Graduate School of Medicine, Kyoto, Japan.

Patrick Jeurissen (P)

Radboudumc, Nijmegen, the Netherlands.

Laura Lange (L)

OptiMedis AG, Hamburg, Germany.

Alexander Pimperl (A)

OptiMedis AG, Hamburg, Germany.

Noriko Sasaki (N)

Kyoto University Graduate School of Medicine, Kyoto, Japan.

Michael Schull (M)

Sunnybrook Research Institute, Toronto, Ontario, Canada.

Joost J G Wammes (JJG)

Radboudumc, Nijmegen, the Netherlands.

Walter P Wodchis (WP)

University of Toronto, Toronto, Ontario, Canada.
Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada.

Gregg S Meyer (GS)

Partners Healthcare System, Boston, Massachusetts, United States of America.
Harvard Medical School, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH